Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Treatment of juvenile idiopathic arthritis

what's new?

Giancane, Gabriellaa,b; Ruperto, Nicolinoa for the Paediatric Rheumatology International Trials Organisation (PRINTO)

doi: 10.1097/BOR.0000000000000632
PEDIATRIC AND HERITABLE DISORDERS: Edited by Polly J. Ferguson
Buy

Purpose of review The present review highlights the advances in disease outcome achieved with currently available biologic medications and future perspectives for JIA management.

Recent findings In the last two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by appropriate legislative initiatives, the existence of very large collaborative networks and the increased availability of the novel biologic medications.

Summary A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans and for a treat-to-target strategy.

aIRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia – PRINTO

bUniversità degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy

Correspondence to Nicolino Ruperto, IRCCS G. Gaslini, Clinica Pediatrica e Reumatologia – PRINTO, Via Gaslini, 5, 16147 Genova, Italy. Tel: +39 1056362795; fax: +39 010 393324; e-mail: nicolaruperto@gaslini.org

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.